Telix Pharmaceuticals Secures First Marketing Authorization in Latin America for Prostate Cancer Imaging Agent Illuccix

ILLUCIX RECEIVES MARKETING AUTHORIZATION IN BRAZIL FOR PROSTATE CANCER IMAGING

São Paulo, Brazil – March 25, 2023 – Dianon Systems, Inc., a leading provider of molecular imaging solutions, announced today that Illuccix, its novel prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent, has received marketing authorization from the Brazilian Health Regulatory Agency (ANVISA) for the diagnosis of prostate cancer in Brazil.

This approval marks the first marketing authorization for Illuccix in Latin America, and it is expected to bring significant benefits to patients and healthcare professionals in Brazil. Illuccix is a breakthrough imaging agent that uses PSMA, a protein highly expressed on prostate cancer cells, to detect and localize prostate cancer.

"Obtaining marketing authorization from ANVISA is a significant milestone for Illuccix in Brazil," said Dr. [Last Name], Chief Medical Officer at Dianon Systems. "We believe that Illuccix has the potential to revolutionize the diagnosis and management of prostate cancer in Brazil, and we look forward to working with healthcare professionals to bring this innovative technology to patients."

The approval was based on data from clinical trials that demonstrated the safety and efficacy of Illuccix in detecting prostate cancer. The agent is administered intravenously and uses a small amount of radioactive material to produce detailed images of the prostate gland and surrounding tissues.

Prostate cancer is a significant public health concern in Brazil, with over 60,000 new cases diagnosed each year. The disease is often diagnosed at an advanced stage, which can make treatment more challenging. Illuccix is designed to help healthcare professionals detect prostate cancer at an early stage, when it is more treatable.

Dianon Systems is committed to making Illuccix available to patients and healthcare professionals in Brazil as soon as possible. The company is working with local partners to establish a distribution network and provide training and support to healthcare professionals.

About Dianon Systems, Inc. Dianon Systems, Inc. is a leading provider of molecular imaging solutions for the diagnosis and management of cancer. The company's products, including Illuccix, are designed to help healthcare professionals detect and localize cancer at an early stage, when it is more treatable. Dianon Systems is headquartered in São Paulo, Brazil, and has operations in the United States and Europe.